Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
4.555
+0.115 (2.59%)
May 2, 2025, 4:00 PM EDT - Market closed
Vanda Pharmaceuticals Revenue
In the year 2024, Vanda Pharmaceuticals had annual revenue of $198.77M with 3.18% growth. Vanda Pharmaceuticals had revenue of $53.19M in the quarter ending December 31, 2024, with 17.48% growth.
Revenue (ttm)
$198.77M
Revenue Growth
+3.18%
P/S Ratio
1.34
Revenue / Employee
$540,141
Employees
368
Market Cap
269.33M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 198.77M | 6.13M | 3.18% |
Dec 31, 2023 | 192.64M | -61.74M | -24.27% |
Dec 31, 2022 | 254.38M | -14.30M | -5.32% |
Dec 31, 2021 | 268.68M | 20.51M | 8.27% |
Dec 31, 2020 | 248.17M | 20.98M | 9.23% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.19B |
Eli Lilly and Company | 49.00B |
Thermo Fisher Scientific | 42.90B |
VNDA News
- 1 day ago - Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 - PRNewsWire
- 10 days ago - FDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA - PRNewsWire
- 27 days ago - Vanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting - PRNewsWire
- 4 weeks ago - Vanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia - PRNewsWire
- 2 months ago - Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S" - PRNewsWire
- 2 months ago - Vanda Pharmaceuticals, Inc. (VNDA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 3 months ago - Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025 - PRNewsWire